Literature DB >> 16154861

Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.

Frédérique Orsini, Chantal Rotschild, Philippe Beurrier, Albert Faradji, Jenny Goudemand, Benoît Polack.   

Abstract

We retrospectively evaluated the efficacy of immune tolerance induction (ITI) in a homogenous cohort of eight patients with constitutive severe hemophilia A with high-responding factor VIII (FVIII) inhibitors using Facteur VIII-LFB/Factane, a highly purified FVIII concentrate containing von Willebrand factor (VWF).

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16154861

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  10 in total

1.  Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

2.  Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 3.  Immune tolerance induction for patients with severe hemophilia A: a critical literature review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

4.  Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.

Authors:  Gianna Franca Rivolta; Caterina Di Perna; Massimo Franchini; Federica Riccardi; Luigi Ippolito; Maria Lombardi; Annarita Tagliaferri
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

5.  A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

Authors:  Giovanni Di Minno; Antonio Coppola
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

Review 6.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 7.  Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B.

Authors:  Abha H Athale; Maura Marcucci; Alfonso Iorio
Journal:  Cochrane Database Syst Rev       Date:  2014-04-24

Review 8.  octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment.

Authors:  Anna Klukowska; Vladimír Komrska; Vladimír Vdovin; Nadezhda Zozulya; Toshko Lissitchkov; Johannes Oldenburg; Carmen Escuriola Ettingshausen
Journal:  Ther Adv Hematol       Date:  2020-04-19

9.  Immune tolerance induction in patients with severe hemophilia A with inhibitors.

Authors:  Ji Eun Ryu; Young Shil Park; Ki Young Yoo; Kyoo Duck Lee; Yong-Mook Choi
Journal:  Blood Res       Date:  2015-12-21

10.  Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real-world report from a single centre, mixed retrospective-prospective long-term study.

Authors:  Saturnino Haya; Carlos Solano; Ana Rosa Cid; Bienvenida Argilés; David Hervás; Felipe Querol; Santiago Bonanad; Pilar Casaña
Journal:  Haemophilia       Date:  2019-01-03       Impact factor: 4.287
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.